PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPirfenidone
Esbriet(pirfenidone)
Esbriet, Pirfenidone (pirfenidone) is a small molecule pharmaceutical. Pirfenidone was first approved as Esbriet on 2011-02-27. It is used to treat pulmonary fibrosis in the USA. It has been approved in Europe to treat idiopathic pulmonary fibrosis, lung diseases, and respiratory tract diseases.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Esbriet, Pirfenidone (discontinued: Esbriet, Pirfenidone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pirfenidone
Tradename
Company
Number
Date
Products
ESBRIETGenentechN-022535 RX2014-10-15
1 products, RLD, RS
ESBRIETGenentechN-208780 RX2017-01-11
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
esbrietNew Drug Application2024-11-20
pirfenidoneANDA2024-11-04
pirfenidone pirfenidoneANDA2023-06-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
pulmonary fibrosis—D011658—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Pirfenidone, Esbriet, Genentech Inc
101886372037-03-28DP
87789472033-08-30U-1613, U-2044, U-2045
78163832030-01-08U-1603, U-2042, U-2050
79106102030-01-08U-1604, U-2048, U-2049
80130022030-01-08U-1603, U-2047, U-2082
80844752030-01-08U-1605, U-2052, U-2054, U-2268
83187802030-01-08U-1606, U-2046, U-2081
86480982030-01-08U-1611, U-2051, U-2052
87541092030-01-08U-1612, U-2053
75667292029-04-22U-1600, U-2077, U-2078, U-2269, U-2270
76357072029-04-22U-1609, U-2072, U-2073, U-2074, U-2075, U-2076, U-2083
85924622029-04-22U-1609, U-2055, U-2056, U-2057, U-2058, U-2059, U-2060, U-2061, U-2062, U-2063
86097012029-04-22U-1610, U-2064, U-2065, U-2066, U-2067, U-2068, U-2069, U-2070
83831502028-05-10DPU-2361
76962362027-12-18U-1601
77677002027-12-18U-1601, U-2080
84206742027-12-18DPU-1608, U-2079
77672252026-09-22DPU-1602
79889942026-09-22DPU-1602
87536792026-09-22DPU-1602
ATC Codes
L: Antineoplastic and immunomodulating agents
— L04: Immunosuppressants
— L04A: Immunosuppressants
— L04AX: Other immunosuppressants in atc
— L04AX05: Pirfenidone
HCPCS
No data
Clinical
Clinical Trials
145 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FibrosisD005355——1421412
Pulmonary fibrosisD011658——1421412
Idiopathic pulmonary fibrosisD054990—J84.1121321411
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung diseasesD008171HP_0002088J98.4—1———1
Interstitial lung diseasesD017563HP_0006530J84.89—1———1
HypertensionD006973EFO_0000537I10—1———1
Pulmonary hypertensionD006976EFO_0001361I27.20—1———1
Heart failureD006333HP_0001635I50—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePirfenidone
INNpirfenidone
Description
Pirfenidone is a pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis. It has a role as a non-narcotic analgesic, a non-steroidal anti-inflammatory drug and an antipyretic.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(=O)n(-c2ccccc2)c1
Identifiers
PDB—
CAS-ID53179-13-8
RxCUI—
ChEMBL IDCHEMBL1256391
ChEBI ID32016
PubChem CID40632
DrugBankDB04951
UNII IDD7NLD2JX7U (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Esbriet – Intermune
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Esbriet – Roche
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 8,953 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
37,197 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use